ALPMY Astellas Pharma Inc (PK)

By Colin Kellaher

Poseida Therapeutics shares surged Monday after the clinical-stage biopharmaceutical company said it would receive a $50 million investment from Astellas that will help support its strategic and operational plans.

Shares of the San Diego company were recently changing hands at $2.56, up about 57%.

Poseida said Astellas is taking an 8.8% stake in the company by investing $25 million for more than 8.33 million shares at $3 apiece, an 84% premium to Friday's closing price of $1.63.

Astellas is also paying $25 million for a right of exclusive negotiation and first refusal to license P-MUC1C-ALLO1, Poseida's allogeneic CAR-T cell therapy in development for multiple solid tumor indications.

Posieda said the investment, along with cost-control measures it has implemented, extend its cash runway into early 2025.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

August 07, 2023 10:26 ET (14:26 GMT)

Astellas Pharma (PK) (USOTC:ALPMY)
과거 데이터 주식 차트
부터 3월(3) 2025 으로 4월(4) 2025

Astellas Pharma (PK) (USOTC:ALPMY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 4월(4) 2025